Category Archives: Regenerative Medicine

IRVINE, Calif., Nov. 1, 2019 /PRNewswire/ --AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that it will be presenting at the following regenerative medicine and investor conferences in November:

Society for the Immunotherapy of Cancer (SITC) Annual MeetingOral PresentationPresenter: Dr. Daniela Bota, MD, PhD, University of California, Irvine; AIVITA GBM Principal InvestigatorTitle: Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastomaTime: November 6-10, 2019Location: Gaylord National Hotel & Convention Center, National Harbor, MD

The Regenerative Medicine Consortium of the Gulf Coast Consortia for Biomedical SciencesOral Presentation Presenter: Dr. Hans S. Keirstead, AIVITA Chairman and CEOTitle: Clinical and Commercial Application of Scaled Human Stem Cell DerivatesTime: November 8, 4:00 PM CTLocation: Bioscience Research Collaborative, Houston, TX

NYC Oncology Investor ConferenceOral Presentation Presenter: Dr. Hans S. Keirstead, AIVITA Chairman and CEO Title: AIVITA Corporate PresentationTime: November 12, 4:50 PM - 5:10 PMLocation: Rockefeller Center, New York, NY

Society for NeuroOncology Annual MeetingPoster PresentationTitle: Phase II trial of AV-GBM-1 (autologous dendritic cells loaded with autologous tumor associated antigens) as adjunctive therapy following primary surgery plus concurrent chemoradiation in patients with newly diagnosed glioblastoma.Time: November 20-24, 2019Location: JW Marriott Desert Ridge, Phoenix, AZ

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. All proceeds from the sale of AIVITA's skin care products support the treatment of women with ovarian cancer.

SOURCE AIVITA Biomedical, Inc.

http://aivitabiomedical.com

Read the original:
AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November - PRNewswire

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today that the company will be added to the S&P/ASX 200 index, effective upon market open on 14 November 2019, two months after being added to the S&P/ASX 300 index.

AVITA Medicals inclusion in the S&P/ASX 200 index is a testament to the companys solid growth trajectory following our U.S. commercialization of the RECELL System combined with the strength of our de-risked pipeline of future indications beyond burns, said Dr. Mike Perry, AVITA Medicals Chief Executive Officer. We believe the market capitalization and trading liquidity of the company will continue to grow as we advance our research and development efforts to realize the full potential of our innovative regenerative medicine technology platform.

The S&P/ASX 200 Index is recognized as the institutional investable benchmark in Australia and measures the performance of the largest 200 companies based on float-adjusted market capitalization on the Australian Securities Exchange.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a REGENERATIVE EPIDERMAL SUSPENSION (RES), an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. Burn Centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

Read the rest here:
AVITA Medical Added to S&P/ASX 200 Index - Business Wire

Do you suffer from chronic knee pain, shoulder pain, hip pain, low back pain, neck pain, degenerative arthritis, bone on bone, or Neuropathy?

Have you tried over the counter medication, prescription drugs, pain medicine, physical therapy, gel shots, Cortisone injections, or surgery, all without lasting relief?

Regenerative Medicine of South Jersey offers cutting edge therapies ideal for improving joint mobility, reducing joint pain and preventing costly painful surgeries or replacements. Regenerative Medicine of South Jersey provides caring state-of-the-art treatment.

Our providers understand the daily struggles that you, or someone you love, endure if you suffer from arthritis, degenerative joint disease, degenerative cartilage and ligaments, bone spurs, Bursitis and Tendinitis, or have been told you are bone-on-bone. We know that people who are diagnosed with these conditions are commonly treated with over-the-counter medications, prescription drugs, pain medicine, physical therapy, injections including cortisone, gel shots (Synvisc, Orthovisc, etc.), and surgery.

As these treatments are performed, the benefits and relief from many of these therapies are short-lived. The result for many of these conditions is major surgery, including total joint replacement, or a life with chronic pain and disability. Many have found success with Regenerative Medicine.

Regenerative therapy takes advantage of your bodys ability to repair itself naturally. The procedure is simple: healing cells are injected into your painful joint by one of our highly trained medical practitioners.

These regenerative cells stimulate an incredible healing force within your body. Over a few weeks to a few months, the cells and growth factors assist your bodys ability to potentially repair and regenerate cartilage, ligaments, muscles, tissues and nerves.

This simple in-office procedure can have an incredible impact on your function, and restore your pain-free life. Regenerative therapy is safe and effective at potentially repairing damaged tissue and reducing pain, while improving your mobility.

Regenerative Medicine of South Jersey holds educational seminars that include vital information on the healing potential of these cells. Visit us online at http://www.regenerativemedicineofsj.com, and call Regenerative Medicine of South Jersey at (609) 886-8039 to register for an informational seminar.

See original here:
Regenerative Medicine May be the Answer for Your Chronic Pain - Cape May County Herald

MIAMI, Nov. 7, 2019 /PRNewswire/ -- The American Academy of Stem Cell Physicians (AASCP) was joined by the alliance leader Janet Marchibroda in hosting a safety standards panel on Nov. 2 at the AASCP Live Congress 2019. The panel which was moderated by Janet Marchibroda, the president of The Alliance for cell therapy now, and included attendance via Skypeby Dr. Peter Marks, director of the Center for Biologics and Evaluation and Research was well-received by physicians from around the world.

The panel discussed safety precautions and considered guidelines for the safety of patients, calling out the bad actors in the field. They noted that current safety guidelines are antiquated and need revision to meet the demands of new cutting-edge medicine such as stem cells, which is a growing field in medical biologics.

Dr. A.J. Farshchian, a spokesperson forthe AASCP, was honored with the 2019 Visionary Award for his pioneering work with the AASCP and the stem cell industry. He said, "There's been too much talk but no action. We need to change that to ensure the safety of the patients who receive care. AASCP will gladly point out the bad actors to the FDA, are we telling on each other? Yes. Are we breaking the Code? No, we are just preserving what's left of this industry."

Later he added, "Many physicians and scientists are starting to believe that some of the regulations regarding stem cells which have been written many years ago have not kept up with the rapidly advancing science. These regulations must be revisited because they are all pass."

At the AASCP Live Congress, board certifications were also provided. To receive the board certification, physicians must meet stringent qualifications, including attending weekly meetings and pass a written and oral exam. The AASCP congratulates those who were recognized, including Dr. Rene Blaha, Dr. Warren Bleiweiss, Dr. Paula Marchionda and Dr. Kalpana Patel, all of whom received diplomat status; and Dr. Max Citrin, who received associate diplomat status.

The American Academy and its board also granted the title of associate professor and all rights therein to Dr. Richard Hull and Dr. Leonid Macheret. Dr. Richard Hull, who also earned tenure with the AASCP, said of the conference, "It is a great pleasure teaching this group of physicians. I love to teach and these physicians are so eager to learn."

To learn more about the AASCP, their educational initiatives and certification, visit AASCP.net.

About AASCP

The American Academy of Stem Cell Physicians (AASCP) is an organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatment, and prevention of disease related to or occurring within the human body. The AASCP aims to serve as an educational resource for physicians, scientists, and the public. To learn more, visit AASCP.net

Related Images

dr-farshchian.jpg Dr. Farshchian

SOURCE The American Academy of Stem Cell Physicians

https://www.aascp.net

Visit link:
At the American Academy of Stem Cell Physicians Live Congress 2019, FDA Safety Panel Says No to the Bad Actors - PRNewswire

LOWELL, Mass., Nov. 5, 2019 /PRNewswire/ --LaunchPad Medical, Inc. announced that it has received a grant from the National Institutes of Health through its Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, to improve strategies for the prevention and treatment for opioid misuse and addiction. This Phase I Small Business Innovation Research (SBIR) grant (1R43DE029369-01) will fund the development of a dental bone graft formulation that will include the release of locally acting non-opioid pain medication. Once developed, this product is intended to be used to fill extraction sites and mitigate post-operative pain following the removal of wisdom teeth.

"Data shows that there is a statistically significant absolute risk increase in persistent opioid use and abuse following a single course of opiates prescribed after wisdom tooth extractions," said George Kay, DMD, MMSc, LaunchPad Medical's Chief Scientific Officer. Approximately 10 million wisdom teeth are removed annually in the United States.

"Preliminary studies have shown that medication can be incorporated into our biomaterial and released over time," said Rahul Jadia, PhD, who is the principal investigator for this grant, "and the release profile of a target drug can be tailored to elicit an ideal time-dose curve."

This grant complements the existing grants that LaunchPad Medical has received from the NIH-funded Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center (U24DE026915) which was formed to improve the translation of promising tissue engineering and regenerative medicine technologies for dental, oral, and craniofacial clinical practice. Funding from the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center has enabled LaunchPad Medical to develop and optimize a dental graft based on the company's Tetranite technology that resorbs and is replaced by bone on a timescale commensurate with existing graft materials but does not require ancillary fixation or containment devices like most other dental graft materials.

"The incorporation of therapeutics into this bone grafting material would further increase the value proposition and clinical utility of this product," said David Kohn, PhD, Director of the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center.

About LaunchPad Medical, Inc.

LaunchPad Medical, Inc. is a medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite. The company is initially developing this technology for use in the dental market, and recently initiated its first-in-man clinical study for implant stabilization. The company is also working to develop adhesive applications for the broader orthopedics market. LaunchPad Medical's Tetranite technology is not yet approved for commercial use.

SOURCE LaunchPad Medical, Inc.

https://www.nih.gov/news-events/news-releases/nih-funds-945-million-research-tackle-national-opioid-crisis-through-nih-heal-initiative

Visit link:
LaunchPad Medical Wins NIH HEAL Grant to Reduce Opioid Use and Addiction - PRNewswire

BOTHELL, Wash., Nov. 7, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that based on revenue growth from 2015 to 2018, it has been selected for inclusion on the Deloitte 2019 Technology Fast 500 list.

Mike Rice, BioLife President and CEO, commented, "We appreciate this recognition of our revenue growth over the last few years. We are focused on building a much larger, world-class enterprise supplying novel and enabling bioproduction tools to the cell and gene therapy industry."

About Deloitte's 2019 Technology Fast 500

Now in its 25th year, Deloitte's Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies both public and private in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2015 to 2018.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least US $50,000, and current-year operating revenues of at least US $5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About BioLife Solutions

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools. Our proprietary CryoStor freeze media and HypoThermosol shipping and storage media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our recently acquired ThawSTAR family of automated cell thawing products and evo cold chain management system reduce therapeutic and economic risk for cell and gene therapy developers by reducing the potential of administering a non-viable dose. For more information, please visit http://www.biolifesolutions.com and follow BioLife on Twitter.

Cautions Regarding Forward Looking Statements

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the company's anticipated business and operations, potential revenue growth and market expansion, and projected financial results. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of our products; market volatility; competition; litigation;the ability of the company to implement its business strategy and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor RelationsRoderick de GreefChief Financial Officer(425) 402-1400rdegreef@biolifesolutions.com

Go here to read the rest:
BioLife Solutions Named one of the Fastest Growing Companies in North America on Deloitte's 2019 Technology Fast 500(TM) - NBC Right Now

"We are excited to have reached this important milestone in the clinical evaluation of INXN-4001 for treatment of end-stage heart failure," stated Amit Patel, MD, MS, Co-Founder and Medical Director of TripleGene. "Heart failure rarely results from a single genetic defect, and while single gene therapy approaches have been studied, these treatments may not fully address the causes of the disease. Our unique multigenic approach is designed to stimulate biological activity targeting multiple points in the disease progression pathway."

Triple-Gene's investigational therapy uses non-viral delivery of a constitutively expressed multigenic plasmid designed to express human S100A1, SDF-1, and VEGF165 gene products, which affect progenitor cell recruitment, angiogenesis, and calcium handling, respectively, and target the underlying molecular mechanisms of pathological myocardial remodeling. The plasmid therapy is delivered via RCSI which allows for cardiac-specific delivery to the ventricle.

"Heart failure is the leading cause of death worldwide and represents a significant and growing global health problem. Aside from heart transplant and LVAD, current treatment options for those patients with end-stage disease are limited," commented Timothy Henry, MD, FACC, MSCAI, Medical Director of the Carl and Edyth Lindner Center for Research and Education at The Christ Hospital and a member of the Triple-Gene Medical Advisory Board. "The INXN4001 investigational therapy represents a biologically-based method focused on repairing the multiple malfunctions of cardiomyocytes, and I look forward to seeing the results of this initial safety study and further exploring the promise of this innovative treatment approach."

Triple-Gene will present preliminary data from the Phase 1 study at theAmerican Heart Association Scientific Sessionsat the Pennsylvania Convention Center in Philadelphia. A poster titled "Safety of First in Human Triple-Gene Therapy Candidate for Heart Failure Patients" will be presented on Sunday, November 17thfrom 3:00 pm - 3:30 pm ETin Zone 4 of the Science and Technology Hall.

About the Phase 1 Trial of INXN-4001INXN-4001 is being evaluated in a Phase I open label study in adult patients with implanted Left Ventricular Assist Device (LVAD). The study is designed to investigate the safety and feasibility of supplemental cardiac expression of S100A1, SDF-1 and VEGF-165 from a single, multigenic plasmid delivered via Retrograde Coronary Sinus Infusion (RCSI) in stable patients implanted with a LVAD for mechanical support of end-stage heart failure. Twelve stable patients with an implanted LVAD were allocated into 2 cohorts (6 subjects each) to evaluate the safety and feasibility of infusing 80mg of INXN4001 in either a 40mL (Cohort 1) or 80mL (Cohort 2) volume. The primary endpoint of safety and feasibility is assessed at the 6-month endpoint. Daily activity data are also collected throughout the study using a wearable biosensor. Dosing on both Cohorts 1 and 2 has been completed, and patients continue follow-up per protocol.

About Triple-GeneTriple-Gene LLC is a clinical stage gene therapy company focused on advancing targeted, controllable, and multigenic gene therapies for the treatment of complex cardiovascular diseases. The Company's lead product is a non-viral investigational gene therapy candidate that drives expression of three candidate effector genes involved in heart failure. Triple-Gene is a majority owned subsidiary ofIntrexon Corporation(NASDAQ: XON) co-founded by Amit Patel, MD, MS, and Thomas D. Reed, PhD, Founder and Chief Science Officer of Intrexon. Learn more about Triple-Gene atwww.3GTx.com.

About Intrexon CorporationIntrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with Better DNAto create biologically-based products that improve the quality of life and the health of the planet through two operating units Intrexon Health and Intrexon Bioengineering. Intrexon Health is focused on addressing unmet medical needs through a diverse spectrum of therapeutic modalities, including gene and cell therapies, microbial bioproduction, and regenerative medicine. Intrexon Bioengineering seeks to address global challenges across food, agriculture, environmental, energy, and industrial fields by advancing biologically engineered solutions to improve sustainability and efficiency. Our integrated technology suite provides industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA, and we invite you to discover more atwww.dna.comor follow us on Twitter at@Intrexon, onFacebook, andLinkedIn.

TrademarksIntrexon, Powering the Bioindustrial Revolution with Better DNA,and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Original post:
Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN4001, First Multigenic Investigational Therapeutic Candidate for...

MEDIA CONTACT

Available for logged-in reporters only

Research Results

SCIENCE

Newswise Trillions of plastic fragments are afloat at sea, which cause large garbage patches to form in rotating ocean currents called subtropical gyres. As a result, impacts on ocean life are increasing and affecting organisms from large mammals to bacteria at the base of the ocean food web. Despite this immense accumulation of plastics at sea, it only accounts for 1 to 2 percent of plastic debris inputs to the ocean. The fate of this missing plastic and its impact on marine life remains largely unknown.

It appears that sunlight-driven photoreactions could be an important sink of buoyant plastics at sea. Sunlight also may have a role in reducing plastics to sizes below those captured by oceanic studies. This theory could partly explain how more than 98 percent of the plastics entering the oceans go missing every year. However, direct, experimental evidence for the photochemical degradation of marine plastics remains rare.

A team of scientists from Florida Atlantic Universitys Harbor Branch Oceanographic Institute, East China Normal University and Northeastern University conducted a unique study to help elucidate the mystery of missing plastic fragments at sea. Their work provides novel insight regarding the removal mechanisms and potential lifetimes of a select few microplastics.

For the study, published in the Journal of Hazardous Materials, researchers selected plastic polymers prevalently found on the ocean surface and irradiated them using a solar simulator system. The samples were irradiated under simulated sunlight for approximately two months to capture the kinetics of plastic dissolution. Twenty-four hours was the equivalent of about one solar day of photochemical exposure in the subtropical ocean gyre surface waters. To assess the physical and chemical photodegradation of these plastics, researchers used optical microscopy, electron microscopy, and Fourier transform infrared (FT-IR) spectroscopy.

Results showed that simulated sunlight increased the amount of dissolved carbon in the water and made those tiny plastic particles tinier. It also fragmented, oxidized and altered the color of the irradiated polymers. Rates of removal depended upon polymer chemistry. Engineered polymer solutions (recycled plastics) degraded more rapidly than polypropylene (e.g. consumer packaging) and polyethylene (e.g. plastic bags, plastic films, and containers including bottles), which were the most photo-resistant polymers studied. Based on the linear extrapolation of plastic mass loss, engineered polymer solutions (2.7 years) and the North Pacific Gyre (2.8 years) samples had the shortest lifetimes, followed by polypropylene (4.3 years), polyethylene (33 years), and standard polyethylene (49 years), used for crates, trays, bottles for milk and fruit juices, and caps for food packaging.

For the most photoreactive microplastics such as expanded polystyrene and polypropylene, sunlight may rapidly remove these polymers from ocean waters. Other, less photodegradable microplastics such as polyethylene, may take decades to centuries to degrade even if they remain at the sea surface, said Shiye Zhao, Ph.D., senior author and a post-doc researcher working in the laboratory of Tracy Mincer, Ph.D., an assistant professor of biology/biogeochemistry at FAUs Harbor Branch and Harriet L. Wilkes Honors College. In addition, as these plastics dissolve at sea, they release biologically active organic compounds, which are measured as total dissolved organic carbon, a major byproduct of sunlight-driven plastic photodegradation.

Zhao and collaborators also checked the biolability of plastic-derived dissolved organic carbon upon marine microbes. These dissolved organics seem to be broadly biodegradable and a drop in the ocean compared to natural biolabile marine dissolved organic carbon. However, some of these organics or their co-leachates may inhibit microbial activity. The dissolved organic carbon released as most plastics photodegraded was readily utilized by marine bacteria.

The potential that plastics are releasing bio-inhibitory compounds during photodegradation in the ocean could impact microbial community productivity and structure, with unknown consequences for the biogeochemistry and ecology of the ocean, said Zhao. One of four polymers in our study had a negative effect on bacteria. More work is needed to determine whether the release of bioinhibitory compounds from photodegrading plastics is a common or rare phenomenon.

Samples in the study included post-consumer microplastics from recycled plastics like a shampoo bottle and a disposable lunch box (polyethylene, polypropylene, and expanded polystyrene), as well as standard polyethylene, and plastic-fragments collected from the surface waters of the North Pacific Gyre. A total of 480 cleaned pieces of each polymer type were randomly selected, weighed and divided into two groups.

Co-authors of the study are Lixin Zhua, a Ph.D. student and lead author, East China Normal University; Thais B. Bittar, Ph.D.; and Aron Stubbins, Ph.D., both at Northeastern University; and Daoji Li, Ph.D., East China Normal University.

This work was supported by national key research and development program of China [2016YFC1402205], the United States National Science Foundation [1910621], The National Science Foundation of China [42676190, 41806137, 41676190), and a graduate fellowship from the Chinese Scholarship Council [201506140016].

- FAU -

About Harbor Branch Oceanographic Institute: Founded in 1971, Harbor Branch Oceanographic Institute at Florida Atlantic University is a research community of marine scientists, engineers, educators and other professionals focused on Ocean Science for a Better World. The institute drives innovation in ocean engineering, at-sea operations, drug discovery and biotechnology from the oceans, coastal ecology and conservation, marine mammal research and conservation, aquaculture, ocean observing systems and marine education. For more information, visit http://www.fau.edu/hboi.

About Florida Atlantic University: Florida Atlantic University, established in 1961, officially opened its doors in 1964 as the fifth public university in Florida. Today, the University, with an annual economic impact of $6.3 billion, serves more than 30,000 undergraduate and graduate students at sites throughout its six-county service region in southeast Florida. FAUs world-class teaching and research faculty serves students through 10 colleges: the Dorothy F. Schmidt College of Arts and Letters, the College of Business, the College for Design and Social Inquiry, the College of Education, the College of Engineering and Computer Science, the Graduate College, the Harriet L. Wilkes Honors College, the Charles E. Schmidt College of Medicine, the Christine E. Lynn College of Nursing and the Charles E. Schmidt College of Science. FAU is ranked as a High Research Activity institution by the Carnegie Foundation for the Advancement of Teaching. The University is placing special focus on the rapid development of critical areas that form the basis of its strategic plan: Healthy aging, biotech, coastal and marine issues, neuroscience, regenerative medicine, informatics, lifespan and the environment. These areas provide opportunities for faculty and students to build upon FAUs existing strengths in research and scholarship. For more information, visit fau.edu.

SEE ORIGINAL STUDY

Original post:
Simulated Sunlight Reveals How 98 Percent of Plastics at Sea Go Missing Each Year - Newswise

Fluicell, a medical technology company spun out from the Chalmers University of Technology, Sweden has launched a high-resolution 3D bioprinter called Biopixlar.This system is an all-in-one discovery platform designed to build novel tissue models fordrug development, as well as disease and regenerative medicine research.

Fluicell biotechnology

Founded in 2012, Fluicell develops platforms for cell behavior investigation. Prior to the release of the Biopixlar 3D printer, the company released its BioPen, reportedly the first single-cell lab-on-a-tip tool for targeting individual cellsin vitro. An ion channel screening platform named the Dynaflow Resolve system was also produced by Fluicell.

As its latest platform, the Biopixlar enablesprinting of multiple different cell types in one run with high precision and resolution. The80cm (H) x 70cm (W) x57cm (D) system includes a micromanipulator arm and a motorized stage to precisely position its printer head and sample.

A unique feature of the Biopixlar is its gamepad interface. This allows for handheldcontrolto position the printer headand deposit cells. Furthermore, an onboard multi-color fluorescence imaging setup allows real-time monitoring of the printing process and post-print analysis.

Biopixlar technical specifications

The production of tissues and disease modelscan complement and decrease animal testing in the intermediate phases of drug development, causing lower development costs and fewer ethical issues. Such models also accelerate the development of personalized medicine with the use of patient-specific cells.According to Fluicell, Biopixlar offers the optimal resolution for medical research models.

The price for the Biopixlar has yet to be disclosed.

Subscribe to the 3D Printing Industry newsletter, like us on Facebook and follow us on Twitter for all the latest 3D bioprinting news. Visit 3D Printing Jobs for new opportunities in additive manufacturing.

Featured image shows Fluicells Biopixlar 3D bioprinter. Photo via Fluicell.

Read more:
Fluicell introduces high resolution 3D bioprinter, the Biopixlar - 3D Printing Industry

NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces presentations at the upcoming 61st American Society of Hematology (ASH) Annual Meeting being held December 7-10, 2019 in Orlando, Florida. The two poster presentations will highlight clinical data from the Phase 1 study of RP-L102 utilizing Process B for the treatment of Fanconi Anemia (FA), as well as long-term follow-up data from the Phase 1/2 EUROFANCOLEN trial.

Details for Rockets poster presentations are as follows:Title: Changing the Natural History of Fanconi Anemia Complementation Group-A with Gene Therapy: Early Results of U.S. Phase I Study of Lentiviral-Mediated Ex-Vivo FANCA Gene Insertion in Human Stem and Progenitor CellsSession Title: Gene Therapy and Transfer: Poster IIPresenter: Sandeep Soni, M.D.Session Date: Sunday, December 8, 2019Session Time: 6:00 p.m. 8:00 p.m. ESTLocation: Orange County Convention Center, Hall B

Title: Hematopoietic Engraftment of Fanconi Anemia Patients through 3 Years after Gene TherapySession Title: Gene Therapy and Transfer: Poster IIIPresenter: Paula Ro, Ph.D.Session Date: Monday, December 9, 2019Session Time: 6:00 p.m. 8:00 p.m. ESTLocation: Orange County Convention Center, Hall B

The Sunday poster session will be followed by a breakout session to give investors and analysts the opportunity to ask questions and discuss the data. The breakout session, hosted by Rocket management, will be held on Sunday, December 8th at 8:30 p.m. EST, directly after Dr. Sonis presentation. At the event, Dr. Soni, Clinical Associate Professor of Stem Cell Transplantation and Regenerative Medicine at the Stanford University School of Medicine and principal investigator of the U.S. Phase 1 trial of RP-L102 and Paula Ro, Ph.D., Senior Scientist, Divisin de Terapias Innovadoras en el Sistema Hematopoytico, CIEMAT/CIBERER Unidad Mixta de Terapias Avanzadas CIEMAT/IIS Fundacin Jimnez Daz will be participating in a Q&A panel. For further information, please contact investors@rocketpharma.com.

About Fanconi Anemia

Fanconi Anemia (FA) is a rare pediatric disease characterized by bone marrow failure, malformations and cancer predisposition. The primary cause of death among patients with FA is bone marrow failure, which typically occurs during the first decade of life. Allogeneic hematopoietic stem cell transplantation (HSCT), when available, corrects the hematologic component of FA, but requires myeloablative conditioning. Graft-versus-host disease, a known complication of allogeneic HSCT, is associated with an increased risk of solid tumors, mainly squamous cell carcinomas of the head and neck region. Approximately 60-70% of patients with FA have a FANC-A gene mutation, which encodes for a protein essential for DNA repair. Mutation in the FANC-A gene leads to chromosomal breakage and increased sensitivity to oxidative and environmental stress. Chromosome fragility induced by DNA-alkylating agents such as mitomycin-C (MMC) or diepoxybutane (DEB) is the gold standard test for FA diagnosis. Somatic mosaicism occurs when there is a spontaneous correction of the mutated gene that can lead to stabilization or correction of a FA patients blood counts in the absence of any administered therapy. Somatic mosaicism, often referred to as natures gene therapy provides a strong rationale for the development of FA gene therapy because of the selective growth advantage of gene-corrected hematopoietic stem cells over FA cells1.

1Soulier, J.,et al. (2005) Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Blood 105: 1329-1336

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rockets multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's clinical programs using LVV-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rockets first clinical program using AAV-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rockets pre-clinical pipeline program is for Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. For more information about Rocket, please visit http://www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to successfully demonstrate the efficacy and safety of such products and pre-clinical studies and clinical trials, its gene therapy programs, the pre-clinical and clinical results for its product candidates, which may not support further development and marketing approval, the potential advantages of Rocket's product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's and its licensors ability to obtain, maintain and protect its and their respective intellectual property, the timing, cost or other aspects of a potential commercial launch of Rocket's product candidates, Rocket's ability to manage operating expenses, Rocket's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Annual Report on Form 10-K for the year ended December 31, 2018. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Read this article:
Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 Process B for Fanconi Anemia at the 61st American Society of Hematology Annual...